A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM.
Paik PK, et al.
Cancer Chemother Pharmacol. 2010 Nov;66(6):1079-85. doi: 10.1007/s00280-010-1265-5. Epub 2010 Feb 18.
Cancer Chemother Pharmacol. 2010.
PMID: 20165849
Free PMC article.
Clinical Trial.